(AOF) – .
Adocia (+190.68% to 11.54 euros)
Adocia posted by far the largest increase in the SRD market in 2023. The biotech specializing in the treatment of diabetes and other metabolic diseases reached a high of 16.16 euros at the end of August. The price took off after the announcement at the beginning of July of the signing of an exclusivity agreement for the benefit of Sanofi on its product M1Pram, which aims to become the reference rapid insulin for diabetes and obesity. The stock subsequently regularly stood out as the biggest riser in the SRD market.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
